Pulmonary artery pressure and the acute chest syndrome in homozygous sickle cell disease

Charles E Denbow, Edward E Chung, Graham R Serjeant

Abstract

Objective—To investigate whether attacks of acute chest syndrome affect pulmonary artery pressure in patients homozygous for sickle cell disease.

Main outcome measures—Pulmonary artery pressure, assessed by non-invasive echocardiographic techniques.

Patients—20 patients with homozygous sickle cell disease with a history of at least six episodes of acute chest syndrome and in 20 age, sex, and height matched controls with homozygous sickle cell disease without a history of acute chest syndrome.

Results—There was no difference in any of the echocardiographic or Doppler indices between these two groups.

Conclusions—Repeated attacks of acute chest syndrome by the mean age of 12 (range eight to 16) years have not had a discernible effect upon pulmonary artery pressure.

Pulmonary fibrosis, and consequently pulmonary hypertension, are believed to compromise right ventricular function resulting in cor pulmonale in some patients with homozygous sickle cell disease. The acute chest syndrome representing a complex pathology of infection, infarction, and pulmonary sequestration is a common cause of morbidity and mortality in homozygous sickle cell disease. The Jamaican cohort study in which children with this disease have been followed up prospectively from birth provides an opportunity to assess the effect of repeated episodes of the acute chest syndrome on pulmonary artery pressure. We report pulmonary haemodynamic findings in 20 age and sex matched pairs with homozygous sickle cell disease with and without a history of multiple episodes of the acute chest syndrome.

Patients and methods

The patients attended the sickle cell clinic of the University Hospital of the West Indies, Kingston, Jamaica, and participated in a cohort study of sickle cell disease. The cohort study was based on all cases of sickle cell disease detected during the screening of 100 000 consecutive normal deliveries at the main Government maternity hospital (Victoria Jubilee Hospital) between June 1973 and December 1981. The study includes 31 children with SS disease of whom 34 have emigrated and 61 have died leaving 220 children aged 10–18·5 years under observation. All children have been followed up prospectively from birth on a schedule of assessments every three months by occasional clinical and radiological assessments. These children all attend the sickle cell clinic as their primary clinic all major events and complications have been recorded from birth.

The acute chest syndrome was defined as a combination of cough, shortage of breath, pleuritic symptoms, and fever in association with clinical signs of parenchymal disease with or without radiological evidence of pulmonary infiltrates. Twenty children of the cohort study had developed six or more attacks of the acute chest syndrome and these were matched by age and sex with 20 SS children without any history of acute chest syndrome. All 40 patients, aged 11–18 years, were studied by echocardiography while clinically well during a three week period in January and February 1992. This was carried out by two cardiologists (EEC, CED) without knowledge of the pulmonary state.

ECHOCARDIOGRAPHIC MEASUREMENTS

Cross sectional echocardiography with Doppler studies were performed with an Advanced Technology Laboratories Ultramark 4 Echocardiograph. The patients were examined in the supine and left lateral positions with the transducer along the third to fifth left intercostal space in the parasternal position. Recordings and measurements were made according to the criteria of the American Society of Echocardiography.

The left ventricular dimension was measured from a point just below the mitral leaflets at the level of the chordae tendineae. The left ventricular end diastolic dimension (Dd) was measured at the onset of the QRS complex of the electrocardiogram, and the left ventricular end systolic dimension (Ds) at the point of maximal posterior movement of the ventricular septum. Left ventricular end diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) were estimated by the methods of Meyer et al. Left ventricular ejection fraction was estimated from the regression equation:

\[
LVEDV = -19.1 + 14.6Dd + 0.02Dd^2
\]

Left ventricular ejection fraction was estimated from the formula:

\[
LVEF = 1 - \frac{(As/Ad)}{Ds/Dd^2}
\]
Pulmonary artery pressure in chest (mm Hg)

- Mean PAP = 0-62
- LVEDV (ml)
- PVR

Cardiac RVET, pressure; ¶n (ms)

- RVET (1/min)
- Pm (mm Hg)
- PVR (dyne s/cm²)
- ACT (ms)
- RVET (ms)

Cardiovascular findings in 20 patients with and without repeated attacks of acute chest syndrome

<table>
<thead>
<tr>
<th>Acute chest syndrome</th>
<th>No acute chest syndrome</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate/min</td>
<td>102 (79-130)</td>
<td>97 (67-125)</td>
</tr>
<tr>
<td>Stroke volume (ml)</td>
<td>80-0 (39-177)</td>
<td>77-5 (48-128)</td>
</tr>
<tr>
<td>Cardiac output (l/min)</td>
<td>8.25 (4-16-1)</td>
<td>7.35 (4-9-16-0)</td>
</tr>
<tr>
<td>Body surface area (m²)</td>
<td>1.22 (0.89-1.53)</td>
<td>1.28 (0.91-1.71)</td>
</tr>
<tr>
<td>Cardiac index (l/min/m²)</td>
<td>7.44 (5.17-4.60)</td>
<td>6.20 (3.47-12.49)</td>
</tr>
<tr>
<td>LVEDV (ml)</td>
<td>135 (66-285)</td>
<td>131 (84-237)</td>
</tr>
<tr>
<td>LVEF</td>
<td>0.62 (0.50-0.75)</td>
<td>0.59 (0.43-0.74)</td>
</tr>
<tr>
<td>Mean PAP (mm Hg)</td>
<td>19.5 (7.43)</td>
<td>19.5 (7.30)</td>
</tr>
<tr>
<td>PAs (mm Hg)</td>
<td>30 (20-39)†</td>
<td>27 (17-34)§</td>
</tr>
<tr>
<td>PAd (mm Hg)</td>
<td>9 (8-10)†</td>
<td>9 (8-14)</td>
</tr>
<tr>
<td>PVR (dyne s/cm²)</td>
<td>148 (54-419)</td>
<td>205 (35-386)</td>
</tr>
<tr>
<td>ACT (ms)</td>
<td>110 (60-120)</td>
<td>100 (80-120)</td>
</tr>
<tr>
<td>RVET (ms)</td>
<td>260 (220-300)</td>
<td>260 (200-320)</td>
</tr>
<tr>
<td>ACT/RVET</td>
<td>0.40 (0.23-0.46)</td>
<td>0.41 (0.32-0.48)</td>
</tr>
</tbody>
</table>

*Wilcoxon test; †Mann-Whitney U test; Number of patients = 20 except for ACT and RVET, where n = 11; n = 10 for RVET.

Discussion

Patients with sickle cell disease are more prone to attacks of acute pulmonary pathology in the absence of a clear pathological mechanism is usually referred to as the acute chest syndrome. In the Jamaican cohort study of sickle cell disease, the incidence of the acute chest syndrome was four times greater than in normal controls by the age of four years. Although the acute chest syndrome is important to morbidity and mortality at all ages, it is unclear whether patients recovering from attacks sustain permanent damage to the alveolar or pulmonary capillary system.

A recent review of experience with acute chest syndrome in the cohort study noted that 31 patients had had six episodes or more by a mean age of 12 years and controlled observations in 20 of these patients noted a significant reduction in peak expiratory flow (PEF) compared with 20 controls with homozygous sickle cell disease matched for age, sex, and height who had never had the acute chest syndrome. The mechanism of reduction in PEF was not clearly understood and could not be investigated further in the absence of other pulmonary function tests, but one possibility was an increased pulmonary fibrosis.

Such a diffuse pulmonary fibrosis might also be expected to reduce the distensibility of pulmonary arterioles and capillaries contributing to an increase in pulmonary artery pressure. It was therefore of interest to study pulmonary artery pressure in the same matched pairs previously studied by PEF to find whether repeated attacks of acute chest syndrome had resulted in an increase in pulmonary artery pressure. We have not detected any significant differences in echocardiographic or Doppler values between the two groups.

This finding is open to several interpretations. The acute chest syndrome may resolve completely without permanent fibrotic changes. The reduction in PEF noted in these children, however, indicates some residual change and Powars et al found a strong co-relation between number of acute chest syndrome events and chronic pulmonary fibrosis (sickle cell chronic lung disease). It is possible that the number of clinical events in these children is still too few to permanently compromise pulmonary vascular flow and that more years of pulmonary events are necessary to exceed the adaptive capacity of the pulmonary vascular bed. This is plausible although Powars et al reported cases of...
chronic lung disease in patients with sickle cell disease before the age of 10 years and an expected trend between mean pulmonary artery pressure and number of acute chest syndrome events did not occur in the present study. Finally it could be argued that there is no relation between pulmonary fibrosis in sickle cell disease and the development of pulmonary hypertension. Although pulmonary hypertension is commonly assumed to be present in sickle cell disease, well documented cases are few. Collins and Orringer found only one case with confirmation of pulmonary hypertension by cardiac catheterisation on careful review of published information, and added two more of their own. On the other hand, a study with Doppler echocardiographic recording of pulmonary artery velocities found evidence of at least moderate pulmonary hypertension in 40% of adults with homozygous sickle cell disease. Although the present study has not used cardiac catheterisation, the validity of the non-invasive method of deriving pulmonary artery systolic pressure from the tricuspid regurgitant velocity has been well documented by simultaneous Doppler and catheterisation studies. Also, the mean pulmonary artery pressure calculated for heart rate correlates well with invasively determined systolic and mean pulmonary artery pressure. There is no reason to believe that this method is invalidated by the cardiovascular changes of sickle cell disease and prospective studies will be continued to clarify the relation between acute chest syndrome events and pulmonary artery pressure in these patients.

We thank Dr Peter Thomas for assistance with the statistical tests and the Sickle Cell Trust for donation of the ATL ultrasound system.